SCHEMBL30258441

SCHEMBL30258441

Cc1oc2cc(Cl)ccc2c1C(=O)c1cc(I)c(O)c(I)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EYA3 Q99504 7/20 0.69
CYP2C19 P33261 4/20 0.69
CYP2C9 P11712 2/20 0.57
LMNA P02545 2/20 0.53
HTT P42858 1/20 0.53
TTR P02766 6/20 0.53
THRA P10827 1/20 0.48
THRB P10828 1/20 0.48
MEN1 O00255 1/20 0.48
BIRC5 O15392 1/20 0.48
ABCB11 O95342 1/20 0.48
PGR P06401 1/20 0.48
HTR1A P08908 1/20 0.48
ADRA2A P08913 1/20 0.48
DRD1 P21728 1/20 0.48
TBXA2R P21731 1/20 0.48
PTGS1 P23219 1/20 0.48
SLC6A2 P23975 1/20 0.48
PDE4A P27815 1/20 0.48
ADORA1 P30542 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26809640 0.83 TTR (0.77) EYA3CYP2C19CYP2C9LMNATTR
SCHEMBL3219908 0.82 EYA3 (1.00) EYA3CYP2C19CYP2C9LMNATTR
SCHEMBL25390899 0.79 EYA3 (0.73) EYA3CYP2C9LMNAHTTTTR
SCHEMBL25391537 0.78 TTR (0.57) EYA3CYP2C19CYP2C9LMNATTR
SCHEMBL25390580 0.76 TTR (0.54) EYA3CYP2C19CYP2C9LMNATTR
SCHEMBL26809685 0.73 TTR (0.71) EYA3CYP2C19CYP2C9LMNATTR
SCHEMBL30357402 0.73 TTR (0.71) EYA3CYP2C19CYP2C9LMNATTR
SCHEMBL30258464 0.71 CYP2C19 (0.73) EYA3CYP2C19CYP2C9LMNAHTT
SCHEMBL30258719 0.71 TTR (0.79) EYA3CYP2C19CYP2C9LMNATTR
SCHEMBL15698044 0.70 EYA3 (1.00) EYA3CYP2C19CYP2C9LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282741-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF INNOVO THERAPEUTICS INC. (KR) 2025-09-11 US claimed
EP-4413981-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Innovo Therapeutics Inc. (KR) 2024-08-14 EP claimed
CN-118043043-A Benzofuranyl hydroxy phenyl ketone derivative compound or pharmaceutically acceptable salt thereof 因诺沃治疗有限公司 2024-05-14 CN claimed
WO-2023059121-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (주)이노보테라퓨틱스 2023-04-13 WO claimed
US-20250282741-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF INNOVO THERAPEUTICS INC. (KR) 2025-09-11 US disclosed
EP-4413981-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Innovo Therapeutics Inc. (KR) 2024-08-14 EP disclosed
CN-118043043-A Benzofuranyl hydroxy phenyl ketone derivative compound or pharmaceutically acceptable salt thereof 因诺沃治疗有限公司 2024-05-14 CN disclosed
WO-2023059121-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (주)이노보테라퓨틱스 2023-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282741-A1 NOVEL BENZOFURANYL HYDROXYPHENYL METHANONE DERIVATIVE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HSPH1, HSP90AA1, HSPD1 EYA3 1904/4885CYP2C19 1346/4885CYP2C9 2435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.